The recent approval of the dry eye disease drug TRYPTYR has heightened competition among pharmaceutical companies. Six years after spinning off from Novartis and going public, eye care company Alcon has secured its first FDA approval for a prescription medication targeting dry eye disease.
The dry eye disease drug, TRYPTYR, is a new TRPM8 receptor agonist formulated to boost tear production and is used as a single drop twice a day. The FDA's approval was supported by results from two Phase III clinical trials in dry eye disease, which included over 930 patients with a history of the condition and were evenly randomized to receive either TRYPTYR or a placebo. ...
